A Randomized, Double-Blind, Placebo-Controlled Study of Oral Milk Immunotherapy for Cow's Milk Allergy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-08-31

Study Completion Date

2008-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if small oral doses of milk protein are safe and effective in decreasing sensitivity to cow's milk in allergic children.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy

NCT00732654

Milk Allergy

COMPLETED PHASE1/PHASE2

Milk Oral Immunotherapy in Children to Treat Food Allergy

NCT01162473

Milk Hypersensitivity

COMPLETED EARLY_PHASE1

Milk Desensitization in Children

NCT03644381

Cow Milk Allergy

UNKNOWN NA

Early Oral Immunotherapy in Infants With Cow's Milk Protein Allergy

NCT03586388

Hypersensitivity, Milk

COMPLETED NA

Effectiveness and Safety of Milk Ladders in Children with IgE-Mediated Cow's Milk Protein Allergy

NCT06664918

Cow Milk Allergy Food Allergy

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, multi-center, clinical trial involving children aged 6 to 21 years with persistent cow's milk allergy. These children will be recruited from 2 sites (Johns Hopkins and Duke University) and will undergo initial screening and double-blind, placebo-controlled, food challenge (DBPCFC) to confirm threshold dose for reactivity to milk. Patients will be treated with milk oral immunotherapy (OIT) or placebo for 22-30 weeks. Those who reach an adequate maintenance dose for OIT will undergo a second DBPCFC. Those who develop desensitization will continue with daily milk intake and undergo a third DBPCFC. Those in the treatment group who are not desensitized will return to strict avoidance. Those in placebo group will be offered to begin treatment or continue with strict milk avoidance. Symptom and diet information will be collected initially and at regular intervals. Bloodwork, skin prick tests (SPTs), pulmonary function tests (PFTs), and oral secretion samples will be done initially and at periodic intervals.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Milk Hypersensitivity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active Treatment

Pre-measured doses of dry, nonfat powered milk prepared by the clinical research-registered dieticians

Group Type EXPERIMENTAL

cow's milk powder

Intervention Type DRUG

Milk powder given orally in escalating doses to a goal of 500 mg for approximately 23 weeks

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cow's milk powder

Milk powder given orally in escalating doses to a goal of 500 mg for approximately 23 weeks

Intervention Type DRUG

Placebo

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provide signed informed consent (by parent or legal guardian if the subject is a minor) and informed assent if applicable
* Age 6 to 21 years
* Must have history of symptomatic reactivity to cow's milk (eczema, urticaria, upper/lower resp., GI, other associated rash, oral symptoms)
* History of positive skin prick test (wheal \>/= histamine control) or milk-Immunoglobulin E (IgE)\>0.35 kilounits per liter (kU/L)
* Positive DBPCFC
* All females of child bearing age must be using appropriate birth control

Exclusion Criteria

* History of anaphylaxis requiring hospitalization
* History of intubation related to asthma
* Has the ability to tolerate \>2.4gram of milk protein at initial DBPCFC
* Has a history of allergy to any component of vehicle
* Pregnancy (need negative test)
* Viral upper respiratory infection (URI) or gastroenteritis within 7days of OFC (OFC needs to be rescheduled)
* Has pulmonary function tests \<80% of predicted (FEV1) or clinical history consistent with moderate persistent asthma
* Currently taking greater than medium dose inhaled corticosteroid (\>400mcg/day fluticasone or fluticasone equivalent if \</=12yo or \>600mcg/day if \>12 years old)
* Antihistamine within 1 week prior to skin testing or food challenges (Skin testing and/or food challenge needs to be rescheduled)
* Systemic corticosteroid within 4 weeks prior to baseline visit
* Receiving omalizumab, beta-blocker, Angiotensin-converting enzyme (ACE) inhibitor or tricyclic antidepressant therapy
* Chronic disease (other than asthma, atopic dermatitis, rhinitis) requiring therapy (e.g., heart disease, diabetes)
* Participation in any interventional study for treatment of a food allergy in the past 12 months
* Severe reaction at initial DBPCFC, defined as:

i. Life-threatening anaphylaxis ii. Requires overnight hospitalization

Minimum Eligible Age

6 Years

Maximum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No